Search academic texts

Information × Registration Number 0221U100898, 0118U003430 , R & D reports Title To improve laboratory monitoring of hemophilia patients treatment on the basis of studying the mechanisms of action of blood clotting preparations using a complex of coagulogic and global tests of hemostasis popup.stage_title Head Stasyshyn Olexandra V., д.мед.н. Registration Date 11-01-2021 Organization State institution "Institute of blood pathology and transfusion medicine of Nataional Academy of Medical scinces of Ukraine" popup.description2 Object: 58 patients with congenital coagulopathies, including 52 hemophilia A patients (24 with inhibitors) and 6 - hemophilia B (1 with inhibitor) aged 1,5 to 60 years. Aim. Based on the study of the mechanisms of action of coagulation factors, to work out parameters for laboratory monitoring of hemostatic therapy in order to optimize and individualize the treatment of hemophilia patients. Methods. Clinical, cytological, hematologic, biochemical, general coagulological studies, thromboelastogram. According to the clinical evaluation of the hemostatic action of bypassing agents (rFVIIa and APCC) in the hemophilia patients with inhibitors, their high efficiency is established. Patients' response to rFVIIa treatment and changes in TEG are individual. The clinical effect correlates with the normalization of TEG parameters 10-15 min after rFVIIa administration. All patients receiving APCC had a clinical effect regardless of its dose . The control of APCC therapy can be performed using TEG at intervals of 30 min to 3 h according to the results of the parameters of the clot formation. TEG can predict the patient's response to rFVIIa and APCC administration. In the prophylactic treatment patients with concizumab or fituziran, the bleeding frequency significantly decreased, indicating the clinical efficacy of the drugs. Regardless of the type of hemophilia and the presence of inhibitors, control of treatment with fituziran is possible using TEG parameters characterizing the hemostatic clot capabilities. The mechanism of action and the effect of the action of fituziran, rFVIIa and APCC are reflected in the TEG at the final stage of the blood clotting process. TEG may be a reliable method of control the therapy of these agents. The algorithm for laboratory control of hemostatic therapy with factor concentrates (ФVIII (IX), rFVIIa, АРСС) and alternative subcutaneous drugs in patients with hemophilia was tested, based on the analysis of coagulation tests and TEG. Product Description popup.authors Dzis Roman P Krasivska Valeriia V Tushnytskyy Orest M popup.nrat_date 2021-01-11 Close